Anthrax: Clinical features, pathogenesis, and potential biological warfare threat

Current Clinical Topics in Infectious Diseases

Volumn , Issue 20, 2000, Pages 335-349

  Friedlander, Arthur M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL MENINGITIS; BIOLOGICAL WARFARE; DISEASE TRANSMISSION; FORECASTING; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; REVIEW;

ANTHRAX; ANTHRAX VACCINES; ANTI-INFECTIVE AGENTS; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; FLUOROQUINOLONES; FORECASTING; HUMANS; MENINGITIS, BACTERIAL; PENICILLINS;

EID: 0034565445     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (115)

1. Klemm DM, Klemm WR. A history of anthrax. J Am Vet Med Assoc 1959;135:458-462.
2. Direkx JH. Virgil on anthrax. Am J Dermatopath 1981;3:191-195.
3. Topley GS, Miles AA. Topley and Wilson's principles of bacteriology and immunity. 4th ed. Baltimore: Williams & Wilkins, 1955: 1938-1954.
4. Koch R. Die aetiologie der Milzbrand-Krankheit, begrundet auf die entwicklungsgeschichte des Bacillus anthracis. Beitrage zur Biologie der Pflanzen 1877;2:277-310. In: Medical Classics 1938;2:787-820.
5. Koch R. Die aetiologie der Milzbrand-Krankheit, begrundet auf die entwicklungsgeschichte des Bacillus anthracis. Beitrage zur Biologie der Pflanzen 1877;2:277-310. In: Medical Classics 1938;2:787-820.
6. Pasteur L. De l'attenuation des virus et de leur retour a la virulence. C R Acad Sci 1881;92:429-435.
7. Tigertt WD. Anthrax. William Smith Greenfield, M.D. FRCP. Concerning the priority due to him for the production of the first vaccine against anthrax. J Hyg 1990; 85:415-420.
8. Logan NA, Turnbull PCB. Bacillus and recently derived genera. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tolken RH, eds. Manual of clinical microbiology. 7th ed. Washington, DC: ASM Press, 1999:357-369.
9. Keim P, Kalif A, Schupp J, et al. Molecular evolution and diversity in Bacillus anthracis as detected by amplified fragment length polymorphism markers. J Bacteriol 1997;179:818-824.
10. Price LB, Hugh-Jones M, Jackson P, Keim P. Genetic diversity in the protective antigen gene of Bacillus anthracis. J Bacteriol 1999; 181:2358-2362.
11. Klevytskya A, Schupp J, Price LB, et al. A multiplexed fluorescent PCR genotyping system based on ten highly informative single-locus markers for B. anthracis strain identification. Abstract. Third International Conference on Anthrax, Plymouth, England, 1998.
12. Manchee RJ, Broster MG, Melling J, et al. Bacillus anthracis on Gruinard Island. Nature 1981;294:254-255.
13. Redmond C, Pearce MJ, Manchee RJ, Berdal BP. Deadly relic of the Great War. Nature 1998;393:747-748.
14. de Vos V. The ecology of anthrax in the Kruger National Park, South Africa. Salisbury Med Bull Suppl 1990;68:19-23.
15. Sterne M. Anthrax. In: Stableforth AW, Galloway IA, eds. Infectious diseases of animals, vol 1. London: Butterworths Scientific Publications, 1959:16-52.
16. de Vos V. Anthrax. In: Coetzer JAW, Thomson GR, Tustin RC, eds. Infectious diseases of livestock, vol 2. New York: Oxford, 1994:1262-1289.
17. Kaufmann AF. Observations on the occurrence of anthrax as related to soil type and rainfall. Salisbury Med Bull Suppl 1990;68: 16-17.
18. de Vos V. The ecology of anthrax in the Kruger National Park, South Africa. Salisbury Med Bull Suppl 1990;68:19-23.
19. McKendrick DRA. Anthrax and its transmission to humans. Central African J Med 1989;26:126-129.
20. Davies JCA. A major epidemic of anthrax in Zimbabwe, II: Distribution of cutaneous lesions. Central African J Med 1983;29:8-12.
21. LaForce FM. Wcolsorters' disease in England. Bull NY Acad Med 1978;54: 956-963.
22. Elkina AV. The epidemiology of a pulmonary form of anthrax. Zh Mikrobiol Epidemiol Immunobiol 1971;48:112-116.
23. Brachman PS. Inhalation anthrax. Ann NY Acad Sci 1980;353:83-93.
24. Glassman HN. World incidence of anthrax in man. Public Health Rep 1958;73:22-24.
25. Brachman P, Friedlander AM. Anthrax. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: W. B. Saunders, 1999:629-637.
26. Morbidity and Mortality Weekly Reports 1997;45:74-78.
27. LaForce FM, Bumford FH, Feeley JC, et al. Epidemiologic study of a fatal case of inhalation anthrax. Arch Environ Health 1969;18: 798-805.
28. Smyth HF, Higgins WD. Anthrax in the United States, 1939-1943. Amer J Pub Health 1945;35:850-858.
29. Eurich FW. Some notes on industrial anthrax: its diagnosis and treatment. Brit Med J 1933;2:50-53.
30. Vessal K, Yeganehdoust J, Dutz W, Kohout E. Radiological changes in inhalation anthrax: a report of radiological and pathological correlation in two cases. Clin Radiol 1975;26:471-474.
31. Severn M. A fatal case of pulmonary anthrax. Brit Med J 1976;1:748.
32. Wyatt V. Maladie de Bradford - after 100 years. New Scientist 1978;79:192-194.
33. Winter H, Pfisterer RM. Inhalationsanthrax bei einem Textilarbeiter: ein nicht-letaler Verlauf. Schweiz med Wschr 1991;121:832-835.
34. Suffin SC, Carnes WH, Kaufmann AF. Inhalation anthrax in a home craftsman. Human Pathology 1978;9:594-597.
35. Davies JCA. A major epidemic of anthrax in Zimbabwe. Part 1. Cent Afr J Med 1982;28: 291-298.
36. Davies JCA. A major epidemic of anthrax in Zimbabwe. Cent Afr J Med 1985;31:176-180.
37. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare: a historical perspective. JAMA 1997;278:412-417.
38. Harris SH. Factories of death. New York: Routledge, 1994.
39. Kadlec RP, Zelicoff AP, Vrtis AM. Biological weapons control: prospects and implications for the future. JAMA 1997;278:351-356.
40. Robertson AG, Robertson LJ. From asps to allegaions: biological warfare in history. Military Medicine 1995;160:369-373.
41. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993;90:2291-2294.
42. Walker DH, Yampolska L, Grinberg LM. Death at Sverdlovsk: what have we learned? Am J Path 1994;144:1135-1141.
43. Zilinskas RA. Iraq's biological weapons: the past as future? JAMA 1997;278:418-424.
44. Cole LA. The specter of biological weapons. Sci Amer 1996;275:60-65.
45. WuDunn S, Miller J, Broad W. How Japan germ terror alerted world. New York Times May 26, 1998:1-6.
46. Office of Technology Assessment, U.S. Congress. Proliferation of weapons of mass destruction: assessing the risks, OTA-ISC-559. Washington, DC: U.S. Government Printing Office, 1993:52-55.
47. Cieslak TJ, Eitzen EM Jr. Clinical and epidemiologic principles of anthrax. Emerg Infect Dis 1999;5:552-555.
48. Green BD, Battisli L, Koehler TM, Thome CB. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 1985;49: 291-297.
49. Uchida I, Sekizaki T, Hashimoto K, Terkado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J Gen Microbiol 1985;131:363-367.
50. Bail O. In: Sterne M. Anthrax. In: Stableforth AW, Galloway, IA, eds. Infectious diseases of animals, vol 1. London: Butterworths Scientific Publications, 1959:22.
51. Ivins BE, Ezzell JW, Jemski J, et al. Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun 1986;52: 454-458.
52. Sterne M. Anthrax. In: Stableforth AW, Galloway IA. Infectious diseases of animals, vol 1. London: Butterworths Scientific Publications, 1959:16-52.
53. Kcppie J, Harris-Smith PW, Smith H. The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action. Brit J Exper Path 1963;44: 446-453.
54. Mikesell P, Ivins BE, Ristroph JD, Dreier TM. Evidence for plasmid mediated toxin production in Bacillus anthracis. Infect Immun 1983;39:371-376.
55. Smith H, Keppie J. Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature 1954;173:869-870.
56. Stanley JL, Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol 1961;26:49-66.
57. Beall FA, Taylor MJ, Thorne CB. Rapid lethal effects in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol 1962;83:1274-1280.
58. Duesbury NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280: 734-737.
59. Vitale G, Pellizzari R, Rccchi C, et al. Anthrax lethal factor cleaves the N-terminus of MAPKK and induces tyrosine/threonine phosphorylation in cultured macrophages. Biochem Biophys Res Commun 1998;248: 706-711.
60. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of enkaryotic cells. Proc Natl Acad Sci USA 1982;79: 3162-3166.
61. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 1986;261: 7123-7126.
62. Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci USA 1993;90:10198-10291.
63. O'Brien J, Friedlander A, Dreier T, et al. Effects of anthrax toxin components on human neutrophils. Infect Immun 1985;47: 306-310.
64. Wright GG, Read PW, Mandell GL. Lipopolysaccharide releases a priming substance from platelets that augments the oxidative response of polymorphonuclear neutrophils to chemotactic peptide. J Infect Dis 1988;157:690-696.
65. Hoover DL, Friedlander AM, Rogers LC, et al. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun 1994;62:4432-4439.
66. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957;73: 485-494.
67. Lincoln RE, Walker JS, Klein F, et al. Value of field data for extrapolation in anthrax. Fed Proceedings 1967;26:1558-1562.
68. Greenfield WS. Further investigations on anthrax and allied diseases in man and animals. Lecture IV. Lancet January 29, 1981: 163-164.
69. Plotkin SA, Brachman PS, Utell M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med 1960;29:992-1001.
70. Brooksher WR Jr, Briggs JA. Pulmonary anthrax: report of a case. JAMA 1920;75: 323-324.
71. Cowdery JS. Primary pulmonary anthrax with septicemia. Arch Path 1947;43:396-399.
72. Gold, H. Anthrax: a report of one hundred seventeen cases. AMA Arch Intern Med 1955; 96:387-396.
73. Hodgson AE. Cutaneous anthrax. Lancet 1941;1:811-813.
74. Dutz W, Kohout E. Anthrax. Pathol Annual 1971:209-248.
75. Doganay M, Bakir M, Dokmeta I. A case of cutaneous anthrax with toxaemic shock. Brit J Derm 1987;117:659-662.
76. Dutz W, Saidi F, Kohout E. Gastric anthrax with massive ascites. Gut 1970;11:352-354.
77. Nalin DR, Sultana B, Sahunja R, et al. Survival of a patient with intestinal anthrax. Am J Med 1977;62:130-132.
78. Jena GP. Intestinal anthrax in man: a case report. Cent African J Med 1980;26:253-254.
79. Bhat P, Mohan DN, Srinivasa H. Intestinal anthrax with bacteriological investigations. J Infect Dis 1985;152:1357-1358.
80. Alizad A, Ayoub EM, Makki N. Intestinal anthrax in a two-year-old child. Ped Infect Dis J 1995;14:394-395.
81. Tekin A, Bulut N, Unal T. Acute abdomen due to anthrax. Brit J Surg 1997;83:813.
82. MacDonald WD. Anthrax: report of a fatal case involving the cutaneous and gastrointestinal systems. New Engl J Med 1942;226: 949-951.
83. Sirisanthana T, Navachareon N, Thaiavichitkul P, et al. Outbreak of oral-pharyngeal anthrax. Am J Trop Med Hyg 1984;33:144-150.
84. Doganay M, Almac A, Hanagasi R. Primary throat anthrax: a report of six cases. Scand J Infect Dis 1986;18:415-419.
85. Haight TH. Anthrax meningitis: review of literature and report of two cases with autopsies. Am J Med Sci 1952;224:57-69.
86. Levy LM, Baker N, Meyer MP, et al. Anthrax meningitis in Zimbabwe. 1981;27:101-104.
87. Lalitha MK, Mathai D, Thomas K, et al. Anthrax: a continuing problem in southern India. Salisbury Med Bull Suppl 1996;87: 14-15.
88. Shanahan RH, Griffin JR, von Auersperg AP. Anthrax meningitis: report of a case of internal anthrax with recovery. Amer J Clin Path 1947;17:719-722.
89. Tahernia AC, Hashemi C. Survival in anthrax meningitis. Pediatrics 1972;50:329-332.
90. George S, Mathai D, Balraj V, et al. An outbreak of anthrax meningoencephalitis. Trans Royal Soc Trop Med Hyg 1994;88:206-207.
91. Turnbull PCB, Leppla SH, Broster MG, et al. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 1988; 177:293-303.
92. Buchanan TM, Feeley JC, Hayes PS, Brachman PS. Anthrax indirect microhemagglutination test. J Immunol 1971;107: 1631-1636.
93. Sirisanthana T, Nelson KE, Ezzell J, Abshire TG. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg 1988;39:575-581.
94. Harrison LH, Ezzell JW, Veterinary laboratory Investigation Center, et al. Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis 1989;160:706-710.
95. Shlyakhov E, Rubinstein E. Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis 1996;15:242-245.
96. Pfisterer RM. Eine milzbrandepidemic in der Schweiz. Schweiz Med Wschr 1991;121: 813-825.
97. Christie AB. Infectious diseases: epidemiology and clinical practice, vol. 2. New York: Churchill Livingstone, 1987:997.
98. Severn M. A fatal case of pulmonary anthrax. Brit Med J 1976;1:748.
99. Bradaric N, Punda-Polic V. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet 1992;340:306-307.
100. Lightfoot NF, Scott RJD, Turnbull PCB. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990; 68:95-98.
101. Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991;23:333-335.
102. Odendaal MW, Picterson PM, de Vos V, Botha AD. The antibiotic sensitivity patterns of Bacillus anthracis isolated from the Kruger National Park. Onderstepoort J Vet Res 1991;58:17-19.
103. Mikesell P, Hillanbrand DA, Friedlander AM, Bush K. Antibiotic susceptibility profiles and beta-lactamase activity in strains of Bacillus anthracis. Abstract A-122. American Society of Microbiologists Annual Meeting, 1992.
104. Sumerkan B, Aygen B, Doganay M, Sehmen E. Antimicrobial susceptibility of Bacillus anthracis against macrolides. Salisbury Med Bull Suppl 1996;87:138.
105. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. Development of novel vaccines against anthrax in man. J Biotechnol 1996;44: 155-160.
106. Gochenour WS Jr, Sawyer WD, Henderson JE, et al. On the recognition and therapy of Simian woolsorter's disease. J Hyg 1963;61: 317-322.
107. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-1242.
108. Inglcsby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. JAMA 1999; 281:1735-1745.
109. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-1208.
110. Christie AB. Infectious diseases: epidemiology and clinical practice, vol. 2. New York: Churchill Livingstone, 1987:992.
111. Kunanusont D, Limpakarnjanarat K, Foy HM. Outbreak of anthrax in Thailand. Ann Trop Med Parasitol 1990;84:507-512.
112. Pugh AO, Davies JCA. Human anthrax in Zimbabwe. Salisbury Med Bull Suppl 1990; 68:32-33.
113. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956;54:28-36.
114. Barnes JM. Penicillin and B. anthracis. J Pathol Bacteriol 1947;59:113-125.
115. Bioterrorism alleging use of anthrax and interim guidelines for management - United States, 1998. MMWR 1999;48:69-74.